AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ADMA Biologics, Inc.
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG002NCK5N4
10.68▼ 0.27 (-2.47%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
10.95
Day's Range
10.57 – 10.91
52-Week Range
7.21 – 20.46
Volume
1.7M
Avg Volume
3.2M
Share Statistics
Shares Outstanding
Employees
647
Exchange
XNAS
Listed
2013-10-17
Share count as of July 31, 2026

ADMA Biologics, Inc. (ADMA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about ADMA Biologics, Inc. (ADMA)
What is ADMA Biologics, Inc.'s Market Cap?
ADMA Biologics, Inc.'s Market Cap is $2.4B, based on as-reported figures from SEC (XBRL) filings.
What is ADMA Biologics, Inc.'s Enterprise Value?
ADMA Biologics, Inc.'s Enterprise Value is $2.5B, based on as-reported figures from SEC (XBRL) filings.
What is ADMA Biologics, Inc.'s Trailing P/E?
ADMA Biologics, Inc.'s Trailing P/E is 14.2×, based on as-reported figures from SEC (XBRL) filings.
What is ADMA Biologics, Inc.'s Price / Sales?
ADMA Biologics, Inc.'s Price / Sales is 4.7×, based on as-reported figures from SEC (XBRL) filings.
What is ADMA Biologics, Inc.'s EV / Revenue?
ADMA Biologics, Inc.'s EV / Revenue is 4.8×, based on as-reported figures from SEC (XBRL) filings.
What is ADMA Biologics, Inc.'s EV / EBITDA?
ADMA Biologics, Inc.'s EV / EBITDA is 10.6×, based on as-reported figures from SEC (XBRL) filings.
What is ADMA Biologics, Inc.'s Revenue (TTM)?
ADMA Biologics, Inc.'s Revenue (TTM) is $512.3M, based on as-reported figures from SEC (XBRL) filings.
What is ADMA Biologics, Inc.'s Net Income (TTM)?
ADMA Biologics, Inc.'s Net Income (TTM) is $169.0M, based on as-reported figures from SEC (XBRL) filings.
What is ADMA Biologics, Inc.'s EBITDA?
ADMA Biologics, Inc.'s EBITDA is $232.0M, based on as-reported figures from SEC (XBRL) filings.
What is ADMA Biologics, Inc.'s Diluted EPS (TTM)?
ADMA Biologics, Inc.'s Diluted EPS (TTM) is 0.75, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ADMAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
REVENUES
YoY growth+2.0%-0.3%+18.4%+12.0%
Cost of product revenue
Gross profit
% of revenue69.4%70.5%63.8%56.3%
OPERATING EXPENSES:
Research and development
Plasma center operating expenses
Amortization of intangible assets
Gain on sale of plasma centers——
Selling, general and administrative
Total operating expenses
% of revenue27.2%19.6%18.7%18.3%
INCOME FROM OPERATIONS
% of revenue42.2%50.9%45.1%38.0%
OTHER INCOME (EXPENSE):
Interest and other income——
Interest expense
Loss on extinguishment of debt—
Other expense
Other income (expense), net
INCOME BEFORE INCOME TAXES
Provision for income taxes
NET INCOME
% of revenue30.4%39.6%35.5%27.1%
BASIC EARNINGS PER COMMON SHARE (in Dollars per share)
DILUTED EARNINGS PER COMMON SHARE (in Dollars per share)